

PA-100

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>101657,932</u>	Prepared by <u>JB</u>	Tracking Number <u>5989807</u>	
Examiner-GAU <u>Raymond-1624</u>	Date <u>8/25/04</u>	Week Date <u>8/21/04</u>	
	No. of queries <u>2</u>	<u>IFW</u>	

JACKET			
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION	MESSAGE
a. Page Missing	<p>① Renumbered claim 1 of original claim 585 is in complete. It ends with a semi-colon. Please resolve.</p> <p>② PTO-1449: Please either initial or line through citation (3). Copy provided for reference.</p>
b. Text Continuity	
c. Holes through Data	
d. Other Missing Text	
e. Illegible Text	
f. Duplicate Text	
g. Brief Description	
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
<p>CLAIMS</p> <p>a. Claim(s) Missing</p> <p>b. Improper Dependency</p> <p>c. Duplicate Numbers</p> <p>d. Incorrect Numbering</p> <p>e. Index Disagrees</p> <p>f. Punctuation</p> <p>g. Amendments</p> <p>h. Bracketing</p> <p>i. Missing Text</p> <p>j. Duplicate Text</p> <p>k. Other</p>	
	<p>RESPONSE</p> <p>Thank you initials JB</p> <p>initials</p>



EV 404052962 US

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	3230/0A/US	10/657,932
	APPLICANT	
	Rogers et al.	
	FILING DATE	GROUP
	September 9, 2003	1614

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No	
1.		WO 99/15508	04/01/99	PCT	C07D 239/02		
2.		WO 99/05107	02/04/99	PCT	C07D 211/72		
3.		WO 98/31359	07/23/98	PCT	A61K 31/18		
4.		WO 99/52896	10/21/99	PCT	C07D 401/12		
5.		WO 93/12796	07/08/93	PCT	A61K 31/415		
6.		EP 0 694 543	01/31/96	Europe	C07D 413/04		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
7.		Berge et al., Pharmaceutical Salts, <i>J. Pharm. Sci.</i> , Vol. 66(1), pp. 1-19, January 1977
8.		Vu et al., Angiogenic Activity in Injured Rat Corneas as Assayed on the Chick Chorioallantoic Membrane, <i>Lab. Invest.</i> , Vol. 53(3), pp. 311-319, 1985
9.		Robertson et al., A Quantitative <i>in Vivo</i> Mouse Model Used to Assay Inhibitors of Tumor-induced Angiogenesis, <i>Cancer Res.</i> , Vol. 51, pp. 1339-1344, February 1991
10.		Ribatti et al., New Model for the Study of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane: The Gelatin Sponge/Chorioallantoic Membrane Assay, <i>J. Vasc. Res.</i> , Vol. 34, pp. 455-463, November-December 1997
11.		Carcellar et al., Synthesis and Structure-Activity Relationships of 1-Acyl-4-((-2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists, <i>J. Med. Chem.</i> , Vol. 36, pp. 2984-2997, 1993
12.		Miller, W. H. et al., Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic, <i>J. Med. Chem.</i> , Vol. 43, pp. 22-26, 2000
13.		Pytela et al., Arginine-Glycine-Aspartic Acid Adhesion Receptors, <i>Methods in Enzymology</i> , Vol. 144, pp. 475-489, 1987
14.		Yatohgo et al., Novel Purification of Vitronectin for Human Plasma by Heparin Affinity Chromatography, <i>Cell Structure and Function</i> , Vol. 13, pp. 281-292, 1988

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	3230/0A/US	10/657,932
	APPLICANT	
	Rogers et al.	
	FILING DATE	GROUP
	September 9, 2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
15.		Charo et al., Inhibition of Fibrinogen Binding to GP IIb-IIIa by a GP IIIa Peptide, <i>J. Biol. Chem.</i> , Vol. 266(3), pp. 1415-1421, January 1991
16.		Niiya et al., Increased Surface Expression of the Membrane Glycoprotein IIb/IIIa Complex Induced by Platelet Activation. Relationship to the Binding of Fibrinogen and Platelet Aggregation, <i>Blood</i> , Vol. 70(2), pp. 475-483, August 1987
17.		Zucker, Platelet Aggregation Measured by the Photometric Method, <i>Methods in Enzymology</i> , Vol. 169, pp. 117-133, 1989
18.		Carron et al., A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy, <i>Cancer Res.</i> , Vol. 58(9), pp. 1930-1935, 1998
19.		Lark et al., Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat, <i>J. Bone Miner. Res.</i> , Vol. 16(2), pp. 319-327, 2001
20.		Healy et al., Angiogenesis: a new theory for endometriosis, <i>Hum. Reproductive Update</i> , Vol. 4(5), pp. 736-740, 1998
21.		Cheresh., Structure, function and biological properties of integrin $\alpha_v\beta_3$ on human melanoma cells, <i>Cancer and Metastasis Rev.</i> , Vol. 10, pp. 3-10, 1991
22.		Friedlander, et al., Involvement of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in ocular neovascular diseases, <i>Proc. Natl. Acad. Sci.</i> , Vol. 93, pp. 9764-9769, September 1996
23.		Badger et al., Disease-Modifying Activity of SB 273005, an Orally Active, Nonpeptide $\alpha_v\beta_3$ (Vitronectin Receptor) Antagonist, in Rat Adjuvant-Induced Arthritis, <i>Arthritis & Rheum.</i> , Vol. 44(1), pp. 128-137, January 2001
24.		Brown et al., Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis, <i>Cardiovascular Res.</i> , Vol. 28, pp. 1815-1820, 1994
25.		Seftor et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561, March 1992
26.		Montgomery et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 8856-8860, September 1994
27.		Brooks et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <i>Cell</i> , Vol. 79, pp. 1157-1164, December 1994

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 3 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	3230/0A/US	10/657,932
	APPLICANT	
	Rogers et al.	
	FILING DATE	GROUP
	September 9, 2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
28.		Adamis et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, <i>Amer. J. Ophthalm.</i> , Vol. 118, pp. 445-450, October 1994
29.		Peacock et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, <i>J. Exp. Med.</i> , Vol. 175, pp. 1135-1138, April 1992
30.		Brooks et al., Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, <i>Science</i> , Vol. 264, pp. 569-571
31.		Sato et al., Echistatin Is a Potent Inhibitor of Bone Resorption in Culture, <i>J. Cell. Biol.</i> , Vol. 111, pp. 1713-1723, October 1990
32.		Fisher et al., Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, <i>Endocrinology</i> , Vol. 132(3), pp. 1411-1413, 1993
33.		Choi et al., Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist <i>GpenGRGDSPCA</i> , <i>J. Vasc. Surg.</i> , Vol. 19(1), pp. 125-134
34.		White, Integrins as virus receptors, <i>Current Biology</i> , Vol. 3(9), pp. 596-599, 1993
35.		Friedlander et al., Definition of Two Angiogenic Pathways by Distinct α_v Integrins, <i>Science</i> , Vol. 270, pp. 1500-1502, December 1995

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.